DX Dialogues: VMAT2 inhibitors and future treatments for tardive dyskinesia
Domenick Sportelli, DO, talks about VMAT2 inhibitors and other treatments being investigated for the treatment of tardive dyskinesia.
Transcript
In the past, the way that we treated tardive dyskinesia, these were really just mitigation of their symptoms.
Now we have this amazing opportunity to treat with targeted mechanistic medications
like the VMAT2 inhibitors. [MUSIC PLAYING] So what's amazing about these VMAT2 inhibitors
is that now, you don't have to change the patient's primary psychiatric treatment.
You don't have to augment their psychopharmacology, basically, for the treatment of their schizophrenia or even bipolar disorder. So you have much more patient stability
and, believe it or not, less burdensome side effects overall because the other medicines that we used
had an incredible side effect burden. With tardive dyskinesia, we've seen such advances. Scientists are now also looking at glutamate pathways
and potentially NMDA receptor modulation. They're looking into oxidative stress reduction
and using novel supplements or even pharmaceuticals to reduce oxidative stress. There's even research into transcranial magnetic
stimulation. [AUDIO LOGO]
brain health nervous system
Browse videos by topic categories
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
ALL